Health
Emyria to seek approval for trial evaluating MDMA to treat PTSD – Stockhead
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder…
Link copied toclipboard
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder was rejected on ethics grounds, an ASX-listed drug development company is taking another crack at it.
Emyria (ASX:EMD) announced this morning that in partnership with Mind Medicine Australia it would seek approval for a major clinical trial testing the use of MDMA to alleviate treatment-resistant PTSD.
Emyria managing…
-
Noosa News23 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News23 hours agoE-biker charged with riding dangerously, assaulting cop
-
General22 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands
-
Business16 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today